Radiopharmaceutical therapy offers promise for people with tough-to-treat meningioma brain tumors

A radiopharmaceutical therapy that has successfully extended progression-free survival for patients with neuroendocrine tumors shows early promise for delivering similar benefits to patients with difficult-to-treat meningioma, a type of brain tumor. Findings of the nonrandomized Phase II study were presented at the American Society for Radiation Oncology (ASTRO) Annual Meeting.

Facebook Comments